NOT KNOWN FACTUAL STATEMENTS ABOUT SEMAGLUTIDE WEEK 1-6 BUNDLE

The trial obtained the two its Major endpoints, with semaglutide two.four mg demonstrating statistically important and outstanding enhancements in liver fibrosis without worsening of steatohepatitis, together with resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH when compared with placebo.oneThe next seve